Patients with densely innervated tumors do worse than those with less innervated cancers. We hypothesize that neural elements are acquired by a tumor-induced process, called neo-neurogenesis. Here, we use PC12 cells in a simple system to test this hypothesis. PC12 cells extend processes, called neurites, only when appropriately stimulated. Using this system, we show that patient tumors release vesicles (exosomes) which induce PC12 neurite outgrowth. Using a cancer mouse model, we show that tumor cells compromised in exosome release grow slower and are less innervated than controls indicating a contribution of innervation to disease progression. We find that neo-neurogenesis is mediated in part by the axonal guidance molecule, EphrinB1, contained in exosomes. These findings support testing EphrinB1 blockers to inhibit tumor innervation and improve survival.
Main Text:
Introduction: Innervated tumors are more aggressive than less innervated ones (1) (2) (3) (4) (5) (6) (7) . For instance, in prostate cancer, recruitment of nerve fibers to cancer tissue is associated with higher tumor proliferative indices and a higher risk of recurrence and metastasis (5) . Denervation studies in pre-clinical and genetically engineered mouse cancer models support a functional contribution of neural elements in disease progression (8, 9) (10) . These studies strongly indicate that the nervous system is not a bystander but instead an active participant in carcinogenesis and cancer progression. However, a mechanistic understanding of how tumors obtain their neural elements remains unclear. Tumors may acquire innervation by growing within innervated tissues; in other words, neural elements are already present within the microenvironment and the tumor acquires them by default. However, the clinical findings that some tumors of the same tissue are more innervated than others indicate instead an active, tumor-initiated process, similar to neo-angiogenesis and lymphangiogenesis. The possibility that tumors invoke their own innervation, termed neo-neurogenesis, has not been extensively explored (11, 12) .
Extracellular release of neurotrophic factors [e.g. nerve growth factor (NGF)] by tumor cells can contribute to cancer progression (13, 14) . While such a direct mechanism likely contributes to tumor innervation, tumors release additional components which may directly promote neoneurogenesis. Among these are extracellular vesicles such as exosomes. Exosomes are 30-150nm vesicles that package a rich cargo (proteins, DNA, RNA, lipids). Because they are generated by invagination of endocytic vesicles, surface cargo protein topology is preserved as is, presumably, biological activity. Exosomes are released into the extracellular milieu by most, if not all, cells (15) and function as vehicles of intercellular communication (16) (17) . Mounting evidence supports the hypothesis that cancer cells utilize exosomes to induce/promote metastasis and tumor tolerance (17) (18) . Here, we show that tumor released exosomes mediate neoneurogenesis in cancer which contributes to disease progression.
We utilize a murine model of human papillomavirus induced (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) which consists of C57Bl/6 oropharyngeal epithelial cells stably expressing HPV16 viral oncogenes, E6 and E7, H-Ras and luciferase (mEERL cells) (19) (20) (21) (22) . The HPV16 E6 oncoprotein interacts with the cellular phosphatase and tumor suppressor, PTPN13; this interaction results in PTPN13's degradation (20, 21) . This is relevant because PTPN13 interacts with many cellular proteins including EphrinB1 which is also a phosphatase substrate (23) . EphrinB1 is a single pass transmembrane protein ligand that binds and activates the Eph receptor tyrosine kinases. Furthermore, EphrinB1 itself becomes phosphorylated and initiates its own downstream signaling (24) . In HPV-infected cells, PTPN13 expression is compromised and thus EphrinB1 phosphorylation persists and contributes to an aggressive disease phenotype (25) (26) . During development, EphrinB1 functions as an axonal guidance molecule (27) (28) . Here we show that tumor released exosomes package EphrinB1 and stimulate neurite outgrowth of PC12 cells in vitro. Compromise of EphrinB1 expression or function significantly attenuates this activity. Moreover, exosomes purified from human squamous cell carcinoma cell lines and from head and neck cancer patient plasma and tumor also package EphrinB1 as exosomal cargo and harbor neurite outgrowth activity. Consistent with these in vitro findings, mEERL tumors over-expressing EphrinB1 are significantly more innervated than tumors with compromised EphrinB1 function or expression. In addition, mEERL tumors genetically compromised in exosome release are sparsely innervated in vivo and grow slower than controls. Taken together, these data indicate that tumor released exosomes contribute to neo-neurogenesis and that exosomal EphrinB1 potentiates this activity.
Results:
Patient exosomes induce neurite outgrowth. We tested whether patient HNSCCs are innervated by immunohistochemically (IHC) staining formalin-fixed paraffin embedded tumor tissue for β-III tubulin, a neuron specific tubulin isoform. β-III tubulin positive fibers are found coursing throughout the tissue indicating these tumors are indeed innervated ( Figure 1A , "Nerve twigs"). These β-III tubulin positive nerve "twigs" cannot be confused with perineural invasion (PNI). (29, 30) . PNI refers to tumor invading into nerves along the perineural space; neo-neurogenesis refers to nerves invading into tumor. Within the perineural sheath, β-III tubulin positive fibers are packed tightly together in a very organized manner ( Figure 1A , "nerve bundle"). The β-III tubulin positive nerve fibers we have identified are instead coursing as individual, unorganized twigs lacking a perineural sheath ( Figure 1A "nerve twigs" ). Additional IHC staining shows that HNSCCs are negative for tyrosine hydroxylase (sympathetic marker) and VIP (parasympathetic marker) but positive for TRPV1 (sensory marker) ( Figure 1A ) indicating sensory neoinnervation of tumor.
Prior to testing the contribution of exosomes to neo-neurogenesis, we performed validations of our differential ultracentrifugation exosome purification technique (31) . For human blood samples, exosomes were purified from plasma. For human tissue samples, exosomes were similarly purified from conditioned media collected after 48 hours in culture. Scanning electron microscopic analysis of our exosome preparations purified from normal donor plasma yielded vesicles consistent in shape and size (30-150nm) with exosomes ( Figure 1B) . Additionally, atomic force microscopy confirmed a 65-110 nm size ( Figure 1C ) and nanoparticle tracking analysis for counting and sizing exosomes also indicated a size distribution consistent with exosomes ( Figure 1D ) (32) . Taken together, these data indicate that our purification method yields vesicles consistent in size and shape with exosomes.
To test our hypothesis that tumor released exosomes induce neo-neurogenesis, we utilized PC12 cells, a rat pheochromocytoma cell line, as an in vitro screen. When stimulated with NGF (100 ng/ml), PC12 cells differentiate into neuron-like cells and extend neurites (33) . We collected 10ml of blood along with matched tumor tissue from three head and neck cancer patients (patient samples Pt1, Pt2, Pt3). We similarly collected blood from 3 healthy volunteers (Nl1, Nl2, Nl3) as well as adult tonsil tissue (TL). The tonsil was chosen as control tissue since the majority of HPV+ OPSCCs arise in the tonsil. Exosomes were purified, quantified by BCA protein assay and further validated by western blot analysis for the exosome markers CD9 and CD81 ( Figure  1E ). To test whether they harbor neurite outgrowth activity, PC12 cells were treated with 3 g exosomes, fixed 48 hours later and immunostained for β-III tubulin. Neurite outgrowth was quantified using the CellInSight CX7 High Content Analysis Platform and the number of neurites compared. The exosome yield from patient Pt1 was low allowing for analysis of only one replicate while quantities from Pt2 and Pt3 were sufficient for technical replicates. Consistent with the literature, we found that untreated PC12 cells extend very few β-III tubulin positive neurites while those stimulated with NGF do so robustly. Exosomes from all three patients (both plasma and tumor) stimulated significant neurite outgrowth of PC12 cells while exosomes from normal plasma and tonsil had minimal neurite outgrowth activity (Figure 1 F, G) . These data indicate that exosomes from head and neck cancer patients harbor neurite outgrowth activity that is absent in healthy controls. mEERL exosomes induce neurite outgrowth. To model the process of neo-neurogenesis, mice were injected with mEERL cells into the hind limb; tumors were later harvested at endpoint, fixed, embedded and IHC stained for β-III tubulin, TH, VIP and TRPV1. Similar to patient HNSCCs, mEERL tumors harbored β-III tubulin positive nerve twigs that were sensory in nature (TRPV1 positive) ( Figure 2A ). To test whether mEERL released exosomes contribute to neoneurogenesis, cells were cultured in vitro, exosomes purified from conditioned media and tested on PC12 cells. To test the function of EphrinB1 in this process, we generated EphrinB1 modified mEERL cell lines. Stable over-expression of wild-type EphrinB1 has been previously characterized and is referred to as mEERL EphrinB1 (26) . Utilizing CRISPR/Cas9, we genetically engineered mEERL cell lines compromised in EphrinB1 function or expression. EphrinB1 deleted cells are denoted as mEERL EphrinB1 Null1 or Null2 while extracellularly deleted EphrinB1 cells are denoted as mEERL EphrinB1ΔECD. The characterization of these mEERL EphrinB1 CRISPR lines is presented in Supplemental Figures 1 and 2 . Exosomes from mEERL parental cells significantly induced neurite outgrowth of PC12 cells. Over-expression of EphrinB1 increased this activity. Interestingly, exosomes from mEERL EphrinB1ECD, Null 1 and Null 2 cells retain the ability to induce neurite outgrowth ( Figure 2B ). Taken together, these data indicate that mEERL released exosomes promote neurite outgrowth and that while EphrinB1 is not required for this activity, it significantly potentiates it.
Exosomes induce neurite outgrowth without NGF. As mEERL cells can produce NGF (34), we analyzed whole cell lysates and purified exosomes from mEERL parental and EphrinB1 cells by western blot for NGF. We confirmed that mEERL parental and EphrinB1 over-expressing cells produce NGF (present in whole cell lysate, WCL), but showed that it is not packaged within CD9+ exosomes ( Figure 2D ). These data indicate that NGF is not required for exosomemediated neurite outgrowth activity. Given that exosomes purified from mEERL EphrinB1 cells potentiate neurite outgrowth of PC12 cells, we tested whether it was packaged as exosome cargo. Western blot analysis of exosomes indicated that EphrinB1 is indeed packaged within exosomes ( Figure 2E ) which is consistent with the published literature (35) (Exocarta.org). Moreover, while the extracellular domain of EphrinB1 is absent in mEERL EphrinB1ECD exosomes, the intracellular domain remains as cargo. Importantly, EphrinB1 was also found in patient exosomes ( Figure 1E ). As with our human exosome validation, we similarly validated exosomes purified from mEERL cells and found them to be likewise consistent in size and shape with exosomes (see Supplemental Figure 3A -C).
Recent published studies suggest that more stringent methods are critical for eliminating other vesicles and cellular debris from exosome purifications (36) . One such method requires the addition of density gradient centrifugation (37) . To test whether this more stringent methodology purifies exosomes with neurite outgrowth activity, conditioned media from mEERL EphrinB1 cells was collected, subjected to differential ultracentrifugation and subsequently to density gradient centrifugation. Fifteen fractions were collected and fractions 4-13 were analyzed by western blot for CD9 and CD81. Consistent with the published literature, we CD9+ and CD81+ vesicles were present in fraction 8 (38, 39) ; Exosomes purified by differential ultracentrifugation alone ("crude" sample) were also CD9+/CD81+ (Supplemental Figure 3D) . Next, to determine which fractions retained neurite outgrowth activity, fractions 4, 5, 8 and 13 were tested on PC12 cells. "Crude" exosomes were also tested. While fraction 8 and "crude" exosomes demonstrate neurite outgrowth activity, CD9 negative fractions 4, 5 and 13 lacked this activity (Supplemental Figure 3E ). These data indicate that inclusion of density gradient centrifugation concentrates CD9+/CD81+exosomes to a single fraction which retains neurite outgrowth activity. The data also indicate that neurite outgrowth activity is retained in EphrinB1 positive CD9+/CD81+ exosomes.
High-Risk HPV E6 and neurite outgrowth. Thus far, we have tested neurite outgrowth activity from mEERL cells or their derivatives, all of which are HPV+. We next tested exosomes from two HPV+ (SCC47 and 93-VU-147T-UP-6) and two HPV-(SCC1 and SCC19) human squamous cell carcinoma cell lines on PC12 cells and found that the HPV-exosomes harbor significantly less neurite outgrowth activity than the HPV+ exosomes ( Figure 3A) . Since HPV16 induces OPSCC, it is considered a high risk HPV (40) . Low risk HPVs rarely cause cancer. One important difference between high and low risk HPVs is found in their E6 proteins. Only high risk E6 contains a C-terminal PDZ binding motif (PDZBM) which significantly contributes to oncogenic transformation (41) (42). To test the contribution of HPV16 E6 to neurite outgrowth, we tested exosomes from primary human tonsil epithelia (HTE), as well as those stably expressing HPV16 E6 and E7 (HTE E6E7) or exosomes from cells in which the PDZBM of E6 has been deleted (HTE E6E7). We found that expression of full length E6 together with E7 was sufficient to induce neurite outgrowth activity while deletion of E6's PDZBM abrogated this effect ( Figure 3B ). Taken together, these data suggest that HPV16 E6 contributes to neurite outgrowth activity.
Exosomes promote tumor innervation and growth. To test whether EphrinB1 expression affects tumor innervation in vivo, mice were implanted with either mEERL parental, EphrinB1, ΔECD, Null1 or Null 2 cells. Ten days post-implantation, when tumors were palpable, they were harvested and whole tumor lysate subjected to western blot analysis for β-III tubulin. β-III tubulin signals were normalized to GAPDH and quantified by densitometry. EphrinB1 and EphrinB1ΔECD tumors harbor significantly more β-III tubulin compared to mEERL parental tumors ( Figure 4A, 4B ). This in vivo capacity to induce tumor innervation was different from in vitro where EphrinB1ΔECD exosomes induce significantly less neurite outgrowth from PC12 cells than mEERL parental exosomes ( Figure 2B ). This discrepancy likely reflects components within the tumor microenvironment (absent in vitro) that also affect tumor innervation. Similar to the in vitro data, Null 1 and Null 2 tumors were not different from mEERL parental ( Figures 2B,  4A, 4B ). Taken together, these data indicate that full length and truncated EphrinB1 are sufficient to potentiate tumor innervation in vivo while its complete deletion cannot.
To more stringently test the hypothesis that tumor released exosomes induce tumor innervation in vivo and to define its contribution to tumor growth, we utilized CRISPR/Cas9 to genetically modify Rab27A and/or Rab27B in mEERL parental cells. These two small GTPases contribute to exosome release and their knock-down compromises release of CD9+ exosomes (43) (44) (45) . The clone generated is heterozygous for Rab27A and homozygous deleted for Rab27B (mEERL Rab27A -/+ Rab27B -/-). For characterization of this clone, see Supplemental Figure 4 ; exosome samples were normalized to producing cell number. Exosomes from mEERL parental and Rab27A -/+ Rab27B -/-cells were purified and analyzed for CD9 and CD81 by western blot. Exosomes purified from the Rab27A -/+ Rab27B -/-expressed less CD9 which is consistent with previous studies demonstrating a decreased capacity to release exosomes by cells compromised in Rab27A/B expression which is reflected by decreased CD9 expression ( Figure 5A ) (45) . Nanoparticle tracking analysis confirmed the decreased capacity of mEERL Rab27A -/+ Rab27B -/-cells to release exosomes ( Figure 5B ). Moreover, we labeled exosomes with CFDA-SE, a cell permeant fluorescein tracer, and quantified fluorescence. Exosomes from mEERL Rab27A -/+ Rab27B -/-cells had decreased fluorescence relative to mEERL parental exosomes ( Figure 5C ). As a whole, these data confirm that modulation of Rab27A/B expression resulted in decreased exosome release. To test whether compromised exosome release affects neurite outgrowth of PC12 cells, mEERL parental and mEERL Rab27A -/+ Rab27B -/-exosomes were normalized to producer cell number and equivalent volumes applied to PC12 cells. The neurite outgrowth activity of mEERL Rab27A -/+ Rab27B -/-exosomes was significantly attenuated compared to that of exosomes from mEERL parental cells ( Figure 5D ). To test whether compromised exosome release alters innervation in vivo, mice were implanted with mEERL parental or Rab27A -/+ Rab27B -/-cells and tumor growth monitored. Rab27A -/+ Rab27B -/-tumors grew significantly slower than mEERL parental tumors in vivo ( Figure 5E ). Importantly, in vitro proliferation assays show that cell doubling time was not significantly different between mEERL parental and Rab27A -/+ Rab27B -/-cells ( Figure 5F ). To determine whether this decreased capacity to release exosomes affects tumor innervation in vivo, tumors were harvested from mice and 30 g of whole tumor lysate quantified by western blot for β-III tubulin ( Figure 5G ). Due to the delayed growth of the mEERL Rab27A -/+ Rab27B -/-, tumors were harvested at 21 days. Consistent with our hypothesis, Rab27A
-/+ Rab27B -/-tumors were significantly decreased in β-III tubulin as compared to mEERL parental tumors ( Figure 5H ). These data support our hypothesis that tumor released exosomes contribute to neo-neurogenesis and also suggest that neo-neurogenesis affects tumor growth.
Interpretations. Our findings propose a new mechanism for tumor-induced neo-neurogenesis. We show that human and mouse HPV+ HNSCCs are innervated de novo by TRPV1 positive sensory nerves. Moreover, while mEERL tumors secrete NGF, it is not required for neurite outgrowth activity in our in vitro assay nor is it packaged within exosomes. Mechanistically, packaging of full length EphrinB1 as exosome cargo significantly potentiates neurite outgrowth in vitro and tumor innervation in vivo and its deletion significantly attenuates both of these activities. Compromising release of CD9+ exosomes results in significantly decreased tumor growth and innervation in vivo. These pre-clinical studies are supported by findings with human HNSCC samples where HNSCC patient plasma and tumor exosomes harbor neurite outgrowth activity. Taken together, these data indicate that CD9+ exosomes released by HPV+ tumor cells promote tumor innervation and tumor growth in vivo. Exosomes containing EphrinB1 further potentiate this activity. HPV infection could modulate exosome cargo and, in this way, affect neurite outgrowth activity. Alternatively, the effects of HPV and EphrinB1 could be related. In HPV infected cells, E6's interaction with PTPN13 results in the degradation of this phosphatase. As a consequence, EphrinB1 phosphorylation persists. Phosphorylated EphrinB1 interacts with binding partners which could then shuttle along with it into exosomes, a theory supported by our EphrinB1ECD data. If HPV's contribution to neo-neurogenesis and disease progression is via this mechanism, it stands to reason that head and neck cancers would harbor either mutations in PTPN13 or EphrinB1 but not both. In fact, The Cancer Genome Atlas shows that PTPN13 and EphrinB1 alterations are mutually exclusive in HNSCC. This mutual exclusivity extends to breast, ovarian, prostate, liver, lung cancers. Thus, our findings could be significant for other cancers. The data also indicate other exosomal cargo including DNA, RNA, miRNA and lipids should be examined for their neurogenic activity. Whatever the combination of factors involved, it is clear that interventions targeting tumor exosome release or blocking the ability of nerves to respond to exosomes may be of therapeutic value. While this concept requires rigorous testing, should it be proven valid, translation into clinical trial has the potential to be rapid.
One question that requires consideration is what advantage does innervation bestow on the tumor? Nerves generally bundle along with blood vessels, providing ready access to required nutrients. Thus, it is possible that tumors induce their own innervation to provide a rich blood supply and promote tumor growth. Our data support this hypothesis. Consistent with this, EphrinB1 possesses proangiogenic properties (46) (47) . Alternatively, tumor innervation may regulate the local immune response which in many solid cancers, particularly head and neck cancers, critically contributes to disease progression (48) . Importantly, neuro-immune interactions are evolutionarily conserved and critical for homeostasis. Recent clinical trials using electrical stimulation of the vagus nerve demonstrate attenuation of disease severity in rheumatoid arthritis, an autoimmune disease (49) . These and other data support the concept that alterations in neuroimmune interactions participate in disease pathogenesis and that therapeutic modulation of these interactions can restore homeostasis. Thus, tumors may promote their own innervation as a means to dampen immune responses, promote tumor tolerance, disease progression and dissemination. Examining the relationship between tumor innervation, vascularization and immune infiltrates in the tumor will help distinguish between these possibilities. Human: UM-SCC1 and UM-SCC47 cell lines were maintained with DMEM with 10% fetal calf serum and 1% penicillin/streptomycin. Primary human tonsil epithelia were collected under an approved IRB protocol and maintained with KSFM (Gibco, cat # 10724-011). HTE E6/E7 and HTE E6Δ/E7 were generated by retroviral transduction and maintained in E-media as described above.
Mouse: mEERL cells (parental and all derivatives) were maintained with E-medium (DMEM (Corning, cat# 10-017-CV)/Hams F12 (Corning, cat#10-080-CV), 10% exosome depleted fetal calf serum, 1% penicillin/streptomycin, 0.5 µg/ml hydrocortisone, 8.4 ng/ml cholera toxin, 5 μg/ml transferrin, 5 µg/ml insulin, 1.36 ng/ml tri-iodo-thyonine, and 5 ng/ml EGF.
mEERL EphrinB1 CRISPR clones: Two distinct strategies were utilized to generate EphrinB1 null mEERL cell lines; one strategy employed simultaneous double-targeting to remove a large portion of gDNA spanning exons 1-5 (as in (51)) and one utilized single-targeting to produce frame-shift causing indels leading to early termination. Target selection and guide sequence cloning were carried out using the tools and protocol of Ran et al. (52) . PCR assays for the double targeting strategy employed primers external to (1-5Δ Ext.) or within (1-5Δ Int.) the predicted deletion site ( Table 1 ). The external assay should result in a 10,485bp wt amplicon and a 229bp Δ amplicon while the internal assay produces a 330bp wt amplicon and no Δ amplicon. Single target screening utilized PCR to amplify a 330bp region surrounding the target site followed by restriction digest with BslI, the recognition site of which should be destroyed when double strand breaks are incorrectly repaired (Table 1) . 1-5Δ Int. REV 5'-TTCCAGGCCCATGTAGTTG-3' mEERL EphrinB1ΔECD clone: This clone was generated from the double-targeting strategy. PCR assays show the predicted deletion product using primers external to the targeted region and lack of an amplicon using primers within the deletion (Supplemental Figure 1B) . The sequence data shows that Exons 2-4 are deleted; these exons comprise the majority of the extracellular domain of EphrinB1 (Supplemental Figure 1A) . The 5' end of the deletion in exon 1 occurs just after the signal peptide while the 3' end of the deletion in exon 5 is within the transmembrane (TM) domain. Eight amino acids within the TM domain are deleted, however, two additional hydrophobic alanines are incorporated.
mEERL Rab27 CRISPR clones: Knockouts of Rab27 in mEERL cells were created using the general protocol of Ran et al. (52) . Briefly, guide sequences targeting exons of RAB27A, RAB27B, or both were cloned into pSpCas9(BB)-2A-Zeo and transfected singly or in combinations to produce indels or larger deletions, respectively, in one or both genes. Following 5 days of Zeocin selection, single cells were expanded and screened for loss of restriction enzyme sites due to indels or by PCR for large deletions induced by double-targeting. Using this strategy, a single clone was identified for sequencing and further characterization.
Clone mEERL Rab27A -/+ Rab27B -/-: This clone resulted from a strategy for double knock out of RAB27A and RAB27B in which sgRNA's targeted to exon 4 of RAB27A, exon 4 of RAB27B, and a sequence of exon 3 shared by RAB27A and B were co-transfected. PCR revealed a heterozygous, truncated deletion product for Rab27A (Supplemental Figure 5A ) and the expected homozygous deletion amplicon for Rab27B (Supplemental Figure 5B) . RAB27B sequence data indicated distinct repair products at the deletion site; although one allele exhibits an immediate stop codon, it is unclear where the other might terminate. However, western blotting confirms lack of detectable protein (data not shown).
